Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible

Inhibitor Therapeutics, Inc.

Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.
Performance-based compensation includes up to 18 million unvested 4-year warrants, vesting upon milestones such as FDA approval or sale of program.
First SOW involves re-analysis of HP2001 clinical study data and preparing FDA meeting request (Type B/C/D).
Board adopted 2025 Equity Incentive Plan reserving 20 million shares; subject to shareholder approval within 12 months.
Consulting agreement continues indefinitely; each project governed by separate SOWs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.